Skip to Content

Treatment with RVD + stem cell transplant achieved higher PFS vs RV alone In patients with newly diagnosed multiple myeloma

In this MEDtalk Paul Richardson Dana Faber Cancer Institute, presents the data from the randomized phase 3 DETERMINATION trial in which patients with newly diagnosed multiple myeloma were randomly assigned to treatment with lenalidomide, bortezomib, and dexamethasone with and without an autologous stem cell transplant, with all receiving lenalidomide maintenance until progression.

Paul Richardson

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top